Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379789 | 1.00 | KMT2A (0.53) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5385064 | 1.00 | KMT2A (0.53) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5379214 | 1.00 | KMT2A (0.53) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5379742 | 1.00 | KMT2A (0.53) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12087990 | 0.88 | CHRM2 (0.50) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12151312 | 0.88 | CHRM2 (0.50) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5011861 | 0.86 | KMT2A (0.47) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL11146489 | 0.86 | KMT2A (0.47) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL26645908 | 0.85 | KMT2A (0.47) | KMT2ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12091646 | 0.83 | CHRM2 (0.47) | KMT2ACHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828349-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | EXONHIT THERAPEUTICS SA (FR) | 2017-11-28 | — | — | US | disclosed |
| US-9399628-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9314466-B2 | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds | ALLERGAN, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160083371-A1 | 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | EXONHIT THERAPEUTICS SA (FR) | 2016-03-24 | — | — | US | disclosed |
| US-9278943-B2 | Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds | EXONHIT THERAPEUTICS SA (FR) | 2016-03-08 | — | — | US | disclosed |
| US-20160051555-A9 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| US-20150231140-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-20130310383-A1 | 1-ARYL -1-HYDROXY -2,3-DIAMINO-PROPYL AMIN ES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | ALLERGAN, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8513288-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120225881-A1 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYRDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8013000-B2 | 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity | ALLERGAN, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100190792-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC | 2010-07-29 | — | — | US | disclosed |
| EP-2198864-A1 | Pharmaceutical compositions having an analgesic effect and containing 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds | Allergan, Inc. (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20100105687-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| EP-1841423-B1 | USE OF 1- BENZYL-1- HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO PROPIONIC ACID AMIDES AND RELATED COMPOUNDS AS ANALGESICS | ALLERGAN INC (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090088433-A1 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-04-02 | — | — | US | disclosed |
| US-20080312236-A1 | 3-Heteroaryl-3-Hydroxy-2-Amino-Propyl Amines And Related Compounds Having Analgesic And/Or Immuno Stimlant Activity | EXONHIT THERAPEUTICS SA (FR) | 2008-12-18 | — | — | US | disclosed |
| WO-2008109287-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109286-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008011483-A2 | METHODS FOR TREATING CHRONIC PAIN USING 1- (HETERO) ARYL-1-HYDROXY 2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312236-A1 | 3-Heteroaryl-3-Hydroxy-2-Amino-Propyl Amines And Related Compounds Having Analgesic And/Or Immuno Stimlant Activity | OPRL1, OPRM1, MRGPRX2 | KMT2A 1030/4885CHRM2 341/4885CHRM4 229/4885 |
| US-20090088433-A1 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | OPRL1, OPRK1, AADAT | KMT2A 1681/4885CHRM2 574/4885CHRM4 1173/4885 |
| US-20130310383-A1 | 1-ARYL -1-HYDROXY -2,3-DIAMINO-PROPYL AMIN ES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | OPRL1, OPRM1, OPRK1 | KMT2A 1522/4885CHRM2 410/4885CHRM4 364/4885 |
| US-20160083371-A1 | 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | OPRM1, OPRL1, MYD88 | KMT2A 1290/4885CHRM2 310/4885CHRM4 261/4885 |
| US-20100105687-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS | SLC1A2, PNMT, HTR2C | KMT2A 277/4885CHRM2 116/4885CHRM4 344/4885 |
| US-20100190792-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, SLC1A1, GRIN2A | KMT2A 614/4885CHRM2 183/4885CHRM4 210/4885 |
| US-20150231140-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, GRIN2A, GRIN2C | KMT2A 536/4885CHRM2 291/4885CHRM4 337/4885 |
| US-20160051555-A9 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, GRIN2A, GRIN2C | KMT2A 536/4885CHRM2 291/4885CHRM4 337/4885 |
| US-20120225881-A1 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYRDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | OPRK1, OPRL1, HRH2 | KMT2A 2098/4885CHRM2 645/4885CHRM4 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.